OrbiMed’s 10x Genomics TXG Stock Holding History

OrbiMed’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-225,200	Closed	-$8.45M	–	123
2024 Q1	$8.45M	Buy	225,200 +185,400	+466%	+$8.15M	0.15%	87
2023 Q4	$2.23M	Buy	+39,800	New	+$1.73M	0.04%	96
2020 Q3	–	Sell	-92,700	Closed	-$8.28M	–	159
2020 Q2	$8.28M	Hold	92,700	–	–	0.12%	108
2020 Q1	$5.78M	Buy	+92,700	New	+$7.23M	0.1%	102

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

OrbiMed's TXG Position: Q2 2024 in Review

OrbiMed sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 225,200 shares — an estimated $8.45M sold.

OrbiMed first reported a position in TXG in Q1 2020 and held it in 4 quarters. The position peaked at $8.45M in Q1 2024. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

OrbiMed reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
OrbiMed sold 225,200 10x Genomics shares in Q2 2024, an estimated $8.45M.
OrbiMed first reported a position in 10x Genomics in Q1 2020 and held it in 4 quarters.
OrbiMed's 10x Genomics position peaked at $8.45M in Q1 2024.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.